{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Everest Organics Sees Revised Market Assessment Amid Mixed Financial Signals
Everest Organics, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This change comes amid a backdrop of mixed fundamental indicators and notable stock performance over the past year.
Why is Everest Organics falling/rising?
On 27-Nov, Everest Organics Ltd witnessed a decline in its share price, falling by 0.64% to close at ₹412.95. This drop comes amid a broader short-term downtrend, contrasting with the company’s impressive long-term performance relative to the benchmark Sensex.
Everest Organics Faces Intense Selling Pressure Amid Consecutive Losses
Everest Organics Ltd has encountered significant selling pressure on 24 Nov 2025, with the stock registering a sharp decline and exhibiting a complete absence of buyers. The pharmaceutical and biotechnology company’s shares have fallen consecutively over the past two sessions, signalling distress selling and heightened market caution.
Everest Organics Faces Intense Selling Pressure Amid Lower Circuit Lockdown
Everest Organics Ltd experienced a pronounced sell-off on 21 Nov 2025, with the stock hitting its lower circuit and registering only sell orders in the queue. This extreme selling pressure signals distress among investors, as the pharmaceutical and biotechnology company’s shares declined sharply, diverging notably from broader market trends.
Is Everest Organics overvalued or undervalued?
As of November 17, 2025, Everest Organics is considered overvalued with a PE ratio of 65.86, significantly higher than its peers, and despite a strong year-to-date return of 49.14%, its low PEG ratio of 0.32 suggests that its growth prospects may not justify its current price.
Is Everest Organics overvalued or undervalued?
As of November 14, 2025, Everest Organics is fairly valued with a PE ratio of 62.63, an EV to EBITDA ratio of 27.20, and a low PEG ratio of 0.31, indicating strong growth potential compared to peers like Sun Pharma and Divi's Lab, while achieving a year-to-date return of 41.84% against the Sensex's 8.22%.
Is Everest Organics overvalued or undervalued?
As of November 14, 2025, Everest Organics is fairly valued with a PE ratio of 62.63 and a PEG ratio of 0.31, showing strong growth potential compared to peers, while outperforming the Sensex with a year-to-date return of 41.84%.
Is Everest Organics overvalued or undervalued?
As of November 14, 2025, Everest Organics is fairly valued with a PE ratio of 62.63, an EV to EBITDA of 27.20, and a PEG ratio of 0.31, outperforming the Sensex with a year-to-date return of 41.84%, while its valuation is higher than Sun Pharma but lower than Divi's Lab.
Why is Everest Organics falling/rising?
As of 14-Nov, Everest Organics Ltd is seeing a price increase to Rs 427.00, up 4.7%, with strong performance and significant investor interest, as evidenced by a 696.28% rise in delivery volume. The stock has consistently outperformed the Sensex, indicating strong investor confidence.
Everest Organics Q2 FY26: Margin Expansion Amid Revenue Volatility
Everest Organics Limited, the Telangana-based active pharmaceutical ingredients manufacturer, reported a mixed performance in Q2 FY26, with net profit declining 17.73% quarter-on-quarter to ₹1.16 crores from ₹1.41 crores in Q1 FY26, even as the company demonstrated robust margin expansion. On a year-on-year basis, net profit surged 56.76% from ₹0.74 crores in Q2 FY25, driven by improved operational efficiencies despite challenging revenue dynamics. The stock, trading at ₹419.80 with a market capitalisation of ₹407.65 crores, has delivered an extraordinary 259.57% return over the past year, significantly outpacing the broader pharmaceutical sector's 3.82% gain.
How has been the historical performance of Everest Organics?
Everest Organics has experienced a decline in financial performance, with net sales dropping from 197.24 Cr in March 2024 to 159.48 Cr in March 2025, resulting in negative profits and cash flow challenges. The company's operating profit decreased significantly, reflecting volatility and reduced profitability in the latest fiscal year.
Everest Organics Ltd Surges 4.99% Today, Marking 266.43% Yearly Gain and Strong Upward Trend
Everest Organics Ltd is experiencing notable buying activity, with the stock rising significantly today, while the Sensex has declined. Over the past week, it has shown strong performance, outperforming its sector. The stock has also demonstrated impressive year-over-year growth, indicating robust market interest and positive sentiment in the pharmaceuticals sector.
How has been the historical performance of Everest Organics?
Everest Organics has experienced a declining trend in financial performance, with net sales dropping from 197.24 Cr in March 2024 to 159.48 Cr in March 2025, resulting in a loss before tax of 3.24 Cr and a negative EPS of -1.33. The company's operating profit margin also decreased, reflecting significant volatility in profitability and revenue generation.
Why is Everest Organics falling/rising?
As of 24-Oct, Everest Organics Ltd is currently priced at Rs 405.70, reflecting a 4.99% increase and strong recent performance, including a 34.76% year-to-date gain. The stock has consistently outperformed its sector and the Sensex, supported by impressive financial results.
Everest Organics Ltd Surges 4.99%, Marks Third Consecutive Day of Gains with 228.24% Yearly Rise
Everest Organics Ltd is experiencing notable buying activity, with a recent stock increase of 4.99%. Over the past three days, it has gained 8.68%, outperforming its sector. The stock has shown impressive annual returns of 228.24%, reflecting strong momentum amid a challenging market environment.
Why is Everest Organics falling/rising?
As of 20-Oct, Everest Organics Ltd's stock price is declining at 373.30, down 4.98%, and has underperformed its sector by 5.66%. Despite a strong year-to-date return of 24.00%, recent trends indicate a potential correction with significant losses over the past week and month.
Everest Organics Ltd Faces Significant Selling Pressure with 4.99% Price Decline Today
Everest Organics Ltd is experiencing significant selling pressure, marked by consecutive losses and a notable decline in its stock performance. Despite a strong yearly gain, recent trends indicate a shift in market sentiment, with the stock underperforming its sector and showing mixed results against moving averages.
Everest Organics Ltd Faces Selling Pressure, Declines 1.99% Amid Ongoing Losses and Seller Dominance.
Everest Organics Ltd is experiencing notable selling pressure, marking three consecutive days of losses. Despite a strong annual performance, the stock has seen a slight decline over the past week. It remains above several moving averages but is currently below the 5-day average, influencing today's trading activity.
Why is Everest Organics falling/rising?
As of 24-Sep, Everest Organics Ltd is priced at 408.00, with a recent positive trend and a year-to-date growth of 35.53%. Despite a slight weekly decline, it has significantly outperformed the Sensex over the past year, indicating strong investor interest and performance.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
